Publications 2024

Gullhaug A, Haakensen VD, De Ruysscher D, Simone CB, Hotca-Cho AE, Chhabra AM, Hellebust TP, Paulsen EE, Dimopoulos MP, Johansen S (2024)
Lung cancer reirradiation: Exploring modifications to utilization, treatment modalities and factors associated with outcomes
J Med Imaging Radiat Sci (in press)
DOI 10.1016/j.jmir.2024.02.004, PubMed 38429174

Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å (2024)
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
Eur J Cancer, 202, 113973 (in press)
DOI 10.1016/j.ejca.2024.113973, PubMed 38447379

Publications 2023

Langberg CW, Horndalsveen H, Helland Å, Haakensen VD (2023)
Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
Front Oncol, 13, 1217424
DOI 10.3389/fonc.2023.1217424, PubMed 37476372

Publications 2022

Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B (2022)
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
J Thorac Oncol, 18 (2), 181-193
DOI 10.1016/j.jtho.2022.10.003, PubMed 36307040

Gulati G, Tjessem KH, Horndalsveen H, Halvorsen S, Haakensen VD (2022)
[Checkpoint inhibitor-induced myocarditis]
Tidsskr Nor Laegeforen, 142 (18)
DOI 10.4045/tidsskr.21.0817, PubMed 36511752

Horndalsveen H, Alver TN, Dalsgaard AM, Rogg LV, Helbekkmo N, Grønberg BH, Halvorsen TO, Ramberg C, Haakensen VD, Öjlert ÅK, Bjaanaes MM, Helland Å (2022)
Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial
Mol Oncol, 17 (3), 487-498
DOI 10.1002/1878-0261.13330, PubMed 36330681

Khadse A, Haakensen VD, Silwal-Pandit L, Hamfjord J, Micke P, Botling J, Brustugun OT, Lingjærde OC, Helland Å, Kure EH (2022)
Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
Front Oncol, 12, 873532
DOI 10.3389/fonc.2022.873532, PubMed 35574381

Publications 2021

Bjaanæs MM, Sande EPS, Loe Ø, Ramberg C, Næss TM, Ottestad A, Rogg LV, Svestad JG, Haakensen VD (2021)
Improved adaptive radiotherapy to adjust for anatomical alterations during curative treatment for locally advanced lung cancer
Phys Imaging Radiat Oncol, 18, 51-54
DOI 10.1016/j.phro.2021.04.003, PubMed 34258408

Farooqi SJ, Bjaanæs MM, Helland Å, Haakensen VD (2021)
[Immunotherapy for malignant pleural mesothelioma]
Tidsskr Nor Laegeforen, 141
DOI 10.4045/tidsskr.21.0503, PubMed 34505475

Farooqi SJ, Helland A, Haakensen VD, Bjaanaes MM (2021)
Immunotherapy in malignant pleural mesothelioma
Tidsskr. Nor. Laegeforen., 141 (12), 1167-1169

Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å (2021)
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
J Transl Med, 19 (1), 232
DOI 10.1186/s12967-021-02905-3, PubMed 34059094

Terkelsen T, Pernemalm M, Gromov P, Børresen-Dale AL, Krogh A, Haakensen VD, Lethiö J, Papaleo E, Gromova I (2021)
High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers
Mol Oncol, 15 (2), 429-461
DOI 10.1002/1878-0261.12850, PubMed 33176066

Publications 2020

Haakensen VD, Khadse A, Sandhu V, Halvorsen AR, Solberg SK, Jørgensen LH, Brustugun OT, Kure EH, Helland Å (2020)
Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
Int J Cancer, 147 (10), 2957-2966
DOI 10.1002/ijc.33121, PubMed 32468587

Terkelsen T, Russo F, Gromov P, Haakensen VD, Brunak S, Gromova I, Krogh A, Papaleo E (2020)
Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration
Breast Cancer Res, 22 (1), 73
DOI 10.1186/s13058-020-01295-6, PubMed 32605588

Publications 2019

Bergholtz H, Lien TG, Ursin G, Holmen MM, Helland Å, Sørlie T, Haakensen VD (2019)
A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue
J Mammary Gland Biol Neoplasia, 24 (2), 163-175
DOI 10.1007/s10911-018-09423-x, PubMed 30613869

Nygård S, Lingjærde OC, Caldas C, Hovig E, Børresen-Dale AL, Helland Å, Haakensen VD (2019)
PathTracer: High-sensitivity detection of differential pathway activity in tumours
Sci Rep, 9 (1), 16332
DOI 10.1038/s41598-019-52529-3, PubMed 31704995

Publications 2018

Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Lüders T, Engebraaten O, Børresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X (2018)
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
Oncoimmunology, 8 (2), e1537691
DOI 10.1080/2162402X.2018.1537691, PubMed 30713794

Terkelsen T, Haakensen VD, Saldova R, Gromov P, Hansen MK, Stöckmann H, Lingjaerde OC, Børresen-Dale AL, Papaleo E, Helland Å, Rudd PM, Gromova I (2018)
N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome
Mol Oncol, 12 (6), 972-990
DOI 10.1002/1878-0261.12312, PubMed 29698574

Publications 2017

Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG (2017)
Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
Oncotarget, 8 (34), 57121-57133
DOI 10.18632/oncotarget.19078, PubMed 28915659

Saldova R, Haakensen VD, Rødland E, Walsh I, Stöckmann H, Engebraaten O, Børresen-Dale AL, Rudd PM (2017)
Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
Mol Oncol, 11 (10), 1361-1379
DOI 10.1002/1878-0261.12105, PubMed 28657165

Publications 2016

Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J et al. (2016)
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170
Nat Genet, 48 (4), 374-86
DOI 10.1038/ng.3521, PubMed 26928228

Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
Clin Transl Immunology, 5 (11), e109
DOI 10.1038/cti.2016.65, PubMed 27990285

Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, Møller Talman ML, Brunner N, Børresen-Dale AL, Gromov P, Helland Å, Kristensen VN, Gromova I (2016)
Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics
Oncoimmunology, 5 (12), e1248015
DOI 10.1080/2162402X.2016.1248015, PubMed 28123884

Halvorsen AR, Helland Å, Gromov P, Wielenga VT, Talman MM, Brunner N, Sandhu V, Børresen-Dale AL, Gromova I, Haakensen VD (2016)
Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer
Mol Oncol, 11 (2), 220-234
DOI 10.1002/1878-0261.12025, PubMed 28145100

Haakensen VD, Nygaard V, Greger L, Aure MR, Fromm B, Bukholm IR, Lüders T, Chin SF, Git A, Caldas C, Kristensen VN, Brazma A, Børresen-Dale AL, Hovig E, Helland Å (2016)
Subtype-specific micro-RNA expression signatures in breast cancer progression
Int J Cancer, 139 (5), 1117-28
DOI 10.1002/ijc.30142, PubMed 27082076

Publications 2015

Darabi H, McCue K, Beesley J, Michailidou K, Nord S, Kar S, Humphreys K, Thompson D, Ghoussaini M, Bolla MK, Dennis J, Wang Q, Canisius S, Scott CG, Apicella C, Hopper JL, Southey MC, Stone J, Broeks A, Schmidt MK, Scott RJ, Lophatananon A, Muir K, Beckmann MW, Ekici AB et al. (2015)
Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
Am J Hum Genet, 97 (1), 22-34
DOI 10.1016/j.ajhg.2015.05.002, PubMed 26073781

Haakensen VD, Steinfeld I, Saldova R, Shehni AA, Kifer I, Naume B, Rudd PM, Børresen-Dale AL, Yakhini Z (2015)
Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome
Mol Oncol, 10 (1), 59-72
DOI 10.1016/j.molonc.2015.08.002, PubMed 26321095

Potapenko IO, Lüders T, Russnes HG, Helland Å, Sørlie T, Kristensen VN, Nord S, Lingjærde OC, Børresen-Dale AL, Haakensen VD (2015)
Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
Mol Oncol, 9 (4), 861-76
DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580

Publications 2014

Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg F, Naume B, Helland A, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
Genome Biol, 15 (8), 435
DOI 10.1186/PREACCEPT-2333349012841587, PubMed 25146004

Saldova R, Asadi Shehni A, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, Helland A, Yakhini Z, Børresen-Dale AL, Rudd PM (2014)
Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC
J Proteome Res, 13 (5), 2314-27
DOI 10.1021/pr401092y, PubMed 24669823

Publications 2013

Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, Kaspi A, Hu R, Robens J, Nikolskaya T, Haakensen VD, Schnitt SJ, Argani P, Ethington G, Panos L, Grant M et al. (2013)
Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics
Cell Stem Cell, 13 (1), 117-30
DOI 10.1016/j.stem.2013.05.004, PubMed 23770079

Publications 2012

Riis ML, Lüders T, Markert EK, Haakensen VD, Nesbakken AJ, Kristensen VN, Bukholm IR (2012)
Molecular profiles of pre- and postoperative breast cancer tumours reveal differentially expressed genes
ISRN Oncol, 2012, 450267
DOI 10.5402/2012/450267, PubMed 23227362

Publications 2011

Haakensen VD (2011)
Biology of the normal breast: relation to mammographic density and risk of breast cancer
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 1137, 1 b. (flere pag.)
BIBSYS 112766811, ISBN 978-82-8264-155-5

Haakensen VD, Bjøro T, Lüders T, Riis M, Bukholm IK, Kristensen VN, Troester MA, Homen MM, Ursin G, Børresen-Dale AL, Helland Å (2011)
Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas
BMC Cancer, 11, 332
DOI 10.1186/1471-2407-11-332, PubMed 21812955

Haakensen VD, Lingjaerde OC, Lüders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Børresen-Dale AL, Helland A (2011)
Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features
BMC Med Genomics, 4, 77
DOI 10.1186/1755-8794-4-77, PubMed 22044755

Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL (2011)
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
Proc Natl Acad Sci U S A, 109 (8), 2802-7
DOI 10.1073/pnas.1108781108, PubMed 21908711

Publications 2010

Haakensen VD, Biong M, Lingjærde OC, Holmen MM, Frantzen JO, Chen Y, Navjord D, Romundstad L, Lüders T, Bukholm IK, Solvang HK, Kristensen VN, Ursin G, Børresen-Dale AL, Helland A (2010)
Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density
Breast Cancer Res, 12 (4), R65
DOI 10.1186/bcr2632, PubMed 20799965

Publications 2009

Potapenko IO, Haakensen VD, Lüders T, Helland A, Bukholm I, Sørlie T, Kristensen VN, Lingjaerde OC, Børresen-Dale AL (2009)
Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression
Mol Oncol, 4 (2), 98-118
DOI 10.1016/j.molonc.2009.12.001, PubMed 20060370

Publications 2006

Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G (2006)
Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
Int J Cancer, 118 (11), 2877-81
DOI 10.1002/ijc.21709, PubMed 16381016